Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia

PHASE4CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

May 31, 2014

Conditions
HIV
Interventions
DRUG

Unique

Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)

Trial Locations (24)

12004

Hospital General de Castellón, Castellon

15781

Hospital Xeral de Vigo, Santiago de Compostela

18014

Hospital Virgen de las Nieves, Granada

28007

Hospital U. Gregorio Marañón, Madrid

28012

Hospital U. San Cecilio, Granada

28029

Hospital Carlos III, Madrid

28034

Hospital Ramón y Cajal, Madrid

28040

Hospital Clínico San Carlos, Madrid

30003

Hospital Reina Sofía de Murcia, Murcia

30203

Hospital Sta. Lucía/ H. Sta. Mª del Rosell, Cartagena

39011

Hospital U. Marqués de Valdecilla, Santander

43007

Hospital Sant Pau i Santa Tecla, Tarragona

46009

Hospital La Fe, Valencia

46014

Hospital Gral. U. de Valencia, Valencia

46015

Hospital Arnau de Vilanova, Valencia

46017

Hospital U. Dr. Peset, Valencia

48903

Hospital de Cruces, Bilbao

03203

Hospital de Elche, Elche

07011

Hospital Son Espases, Palma de Mallorca

08916

H. U. Germans Trias i Pujol, Badalona

08907

H. de Bellvitge, L'Hospitalet de Llobregat

03010

Hospital Gral. U. de Alicante, Alicante

08035

Hospital Vall d'Hebron, Barcelona

08304

Hospital de Mataró, Barcelona

All Listed Sponsors
lead

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

NCT01378910 - Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia | Biotech Hunter | Biotech Hunter